[Lipodystrophy syndrome in HIV infection]

Area of Science:

• Medicine
• Pharmacology
• Endocrinology

Background:

• Antiretroviral therapy has evolved significantly since the introduction of protease inhibitors in 1997.
• Long-term use of protease inhibitors is associated with emerging side effects, primarily metabolic disturbances.
• Observed metabolic changes include hypertriglyceridemia, hypercholesteremia, and hyperglycemia.

Purpose of the Study:

• To investigate the long-term side effects of protease inhibitor-based antiretroviral therapy.
• To characterize the metabolic changes and fat redistribution associated with this therapy.
• To evaluate the incidence of lipodystrophy in patients receiving protease inhibitors.

Main Methods:

• Observational study of 224 patients undergoing antiretroviral therapy.
• Analysis of patient data for metabolic changes (triglycerides, cholesterol, glucose).
• Assessment of fat redistribution patterns and incidence of lipodystrophy.

Main Results:

• 29 out of 224 patients (13%) developed lipodystrophy.
• 27 of these patients had received protease inhibitors; 17 were treated with indinavir.
• 2 patients who developed lipodystrophy had never received protease inhibitors, suggesting other potential causes.

Conclusions:

• Protease inhibitors are strongly associated with the development of lipodystrophy and metabolic alterations.
• The precise mechanisms underlying these side effects require further investigation.
• Therapeutic strategies may involve protease inhibitor-free regimens or lipid-lowering medications.